Inhibiting Cyclin D1-Cdk6 Suppresses Senescence-Associated Inflammatory Gene Expression And Age-Related Functional Decline
As we age, our bodies accumulate “senescent cells” – cells that have stopped dividing but remain active, often releasing harmful inflammatory signals. This chronic inflammation, known as the senescence-associated secretory phenotype (SASP), contributes to many age-related diseases and overall decline. Researchers have discovered that a protein called cyclin D1 (CCND1) and its partner enzyme, CDK6, play a surprising role in this process. While typically involved in cell division, this duo remains active in senescent cells, where they actually promote DNA damage and trigger further inflammatory responses. By blocking the activity of CCND1-CDK6, either through genetic modification or with a drug called palbociclib (already approved for cancer treatment), scientists observed a significant reduction in inflammatory markers in aged mouse livers. Even more exciting, this intervention also led to a decrease in frailty and an improvement in physical performance in the older mice. These findings suggest that targeting this specific pathway could be a promising strategy to combat the effects of aging and age-related conditions, potentially by repurposing existing medications.
Source: link to paper